Pharmacology
-
First-line zongertinib demonstrates durable responses in HER2-mutant NSCLC
Brett Bade, MD, and Katie Smith, MD, said the expansion of targeted therapies for lung cancer is an important advance, while noting that questions remain regarding the drug’s role in the first-line setting.
-
TETON-1 treatment effects offer hope for patients with idiopathic pulmonary fibrosis
Christopher King, MD, FCCP, and Steven D. Nathan, MD, FCCP, discuss the clinical implications of inhaled treprostinil, including the medication’s potential use in future combination treatment strategies.
-
Setidegrasib demonstrates durable responses in KRAS G12D-mutant NSCLC
Coauthor Anup Kasi, MD, MPH, said the study represents an important step forward in the development of KRAS G12D-targeted therapies.
-
DPP-1 inhibitors enter clinical practice
Sunjay R. Devarajan, MD, FCCP, and Anas Hadeh, MD, FCCP, said DPP-1 inhibitors are expected to become a new standard of care, with ongoing studies further defining their role in noncystic fibrosis bronchiectasis management.
-
Small trial shows lower ARDS rate, mortality with sivelestat following cardiopulmonary bypass
Nicholas Villalobos, MD, said that while sivelestat may not represent a single solution for ARDS, evidence that it can temper the inflammatory cascade is positive.
-
Phase 3 TETON trials demonstrate positive results for inhaled treprostinil for IPF
Steven D. Nathan, MD, FCCP, said the evidence shows the drug is effective for treating pulmonary hypertension and may slow or prevent fibrosis progression.
-
Triple therapy shows meaningful benefits in uncontrolled asthma
Alberto Papi, MD, FCCP, said recent data from the KALOS and LOGOS trials suggest triple therapy may address airflow limitation and exacerbation risk in a single inhaler.
-
Umeclidinium-vilanterol shows modest but consistent advantage among LAMA-LABA options in symptomatic COPD
Investigator William B. Feldman, MD, PhD, MPH, said the findings raise important questions about whether inhalers in the same class are indeed therapeutically equivalent for patients with COPD.
-
Data show oral nalbuphine significantly reduces chronic cough in idiopathic pulmonary fibrosis
Experts discuss the promising results—particularly surrounding patient-reported outcomes in this population—and the need for long-term safety data.
-
Study finds triple combination modulator therapy reduces inflammation in CF
Valentino Bezzerri, PhD, discusses findings from a compassionate-use study examining the effects of elexacaftor/tezacaftor/ivacaftor on inflammation in patients with cystic fibrosis.
